Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hypertension drug shows promise in early safety trial

NCT ID NCT06905327

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage study tested a new drug called QCZ484 in 56 healthy volunteers and people with mild hypertension. The main goal was to check safety and how the body handles the drug. Participants received a single injection of either QCZ484 or a placebo, and researchers monitored for side effects and lab changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
QCZ484
What this could lead to
If successful, this could lead to a new treatment option for mild hypertension.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

56 people

The number who actually took part.

Started

Mar 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males or females aged 18 to 60 years, inclusive, at the time of informed consent. (Part A only). * Males or females aged 18 to 72 years, inclusive, at the time of informed consent (Part B only). * Body mass index (BMI) \>= 18 and \<= 32 kg/m2 and body weight \>50 kg (Part A only). * Body mass index (BMI) \>=18 and \<=35 kg/m2 and body weight \>50 kg (Part B only). * Triplicate 12-lead electrocardiogram (ECG) after \>5 minutes resting without clinically significant findings at screening and Day -1. * Mean sitting systolic blood pressure (SBP) of \>=130 and \<160 mm Hg (Part B only). Exclusion Criteria: * History of hypotension or orthostatic hypotension. * History of syncope within 1 year. * SBP \<90 mmHg or DBP \<60 mm Hg at screening (Part A only). * Clinical laboratory findings outside of range are deemed clinically significant by the investigator at screening. * Any liver function panel analyte value \> 1.2 ×upper limits of normal (ULN) at screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign essential hypertension essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild hypertension

Contacts and locations

Locations

  • Novartis Investigative Site

    Herston, Queensland, 4006, Australia

  • Novartis Investigative Site

    Morayfield, Queensland, 4506, Australia

  • Novartis Investigative Site

    Adelaide, 5000, Australia

  • Novartis Investigative Site

    Auckland, 0622, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.